



## *Dermapharm Holding SE with increased free float*

**Grünwald, July 1, 2019 – Dermapharm Holding SE ("Dermapharm"), a leading manufacturer of patent-free branded drugs for selected therapeutic areas in Germany with a growing international presence, has been informed by Themis Beteiligungs-Aktiengesellschaft ("Themis") that on June 28, 2019 580,000 shares of Dermapharm for the price of 30.00 Euros per share have been sold outside a trading venue.**

The 580,000 shares were initially to be sold as part of the Greenshoe option already during the IPO. In the course of stabilisation measures following the successful IPO, the stabilisation manager bought back the shares already placed and then returned them to Themis.

Following the sale, the shareholder structure is now composed as follows: At 75.05% (previously 76.13%), the majority of the no-par shares continue to be held by Themis. 24.95% (previously 23.87%) of the shares of Dermapharm are in free float.

For the time being Dermapharm expects that Themis will not further reduce its share in Dermapharm.

### **Company profile:**

#### **Dermapharm – Pharmaceutical Excellence "Made in Germany"**

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company's integrated business model comprises in-house development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 900 marketing authorizations (*Arzneimittelzulassungen*) for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company's core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm's business model also includes a parallel import business, which operates under the "axicorp" brand. Based on revenues, Dermapharm was among the top five parallel import companies in Germany in 2018. In the "Herbal Extracts" segment, Dermapharm has access to the growth market for plant pharmaceuticals through the Spanish company Euromed S.A., one of the leading manufacturers of plant extracts and plant-based active ingredients.

With a consistent development strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimized its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue this profitable growth course in the future. The company is focusing on a three-pillar strategy: in-house development of new products, increase of its international footprint and further acquisitions.

### **Contacts**

Investor Relations  
Britta Hamberger  
Phone: +49 (0)89 – 64186-233  
Fax: +49 (0)89 – 64186-165  
e-mail: [ir@dermapharm.com](mailto:ir@dermapharm.com)

cometis AG  
Claudius Krause  
Phone: +49 (0)611 – 205855-28  
Fax: +49 (0)611 – 205855-66  
e-mail: [ir@dermapharm.com](mailto:ir@dermapharm.com)